The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Bayas A, Menacher M, Schwaiblmair M, Märkl B, Naumann M

Alemtuzumab-associated diffuse alveolar damage - a case report.

BMC neurology 2020 Sep 23;20;357 — 2020 Sep 23 — 357

Bianco A, Mari PV, Larici AR, Lucchini M, Nociti V, Losavio FA, De Fino C, Cicchetti G, Coraci D, Richeldi L, Mirabella M

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.

Multiple sclerosis and related disorders 2019 Oct 15;37;101450 — 2019 Oct 15 — 101450

Whiteside D, Barth S, Datta A, Trip SA

Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.

Multiple sclerosis and related disorders 2018 May;22;139-140 — 2018 May — 139-140

Blasco MR, Ramos A, Malo CG, García-Merino A

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.

Journal of neurology 2017 Jan;264;168-169 — 2017 Jan — 168-169